A Tissue Implantable Microbiosensor

描述(申请人提供)：在这一第二阶段的SBIR中，我们将商业化组织植入型30μm微生物传感器，用于测量自由活动动物的葡萄糖、乳酸和氧气。我们还将开发并商业化由葡萄糖生物传感器、乳酸生物传感器和氧气传感器组成的传感器阵列。与微透析相比，生物传感器提供了高时间分辨率和低分析物消耗。目前，最先进的生物传感器(O.D.100-250μm)已被证明在测量自由活动的啮齿动物大脑中的一系列分析物方面具有价值。与目前的微透析和生物传感器技术相比，减小生物传感器直径将大大减少对脑组织的损害，并提高解剖学的准确性。顶峰公司将领导这项提议，并与堪萨斯大学三位顶尖科学家组成的跨学科联盟合作。任申强教授在材料科学和纳米制造技术方面拥有丰富的经验，Mark Richter教授在蛋白质工程方面非常熟练，George Wilson教授为该项目带来了30多年的生物传感器开发经验。顶峰公司和堪萨斯大学各实验室现有的设施和设备将提供成功完成这一项目所需的资源。这一提议的创新方面包括：生物传感器制造中的新技术，如纳米刻蚀，以及通过电泳操纵酶固定的纳米颗粒，以及将皮升的底物常规和精确地沉积到定义好的井中的能力。在第一阶段，我们的团队在开发30μm葡萄糖微生物传感器原型方面取得了几项重大进展。我们生产的功能原型可以线性测量葡萄糖到至少20 mm，拒绝抗坏血酸盐和尿酸盐，并有效地回收电极表面的O2。这些初步结果构成了第二阶段提案的基础。这些 植入式30μm微生物传感器有可能显著提高对药物-神经元相互作用背后的机制的理解。这将深刻改变制药和生物技术公司的药物发现格局，提高药物开发效率。此外，空间分辨率的提高和炎症反应的减少将使研究人员能够识别新的神经过程，从而为常见疾病带来新的理解、方法和解决方案。生物传感器在2009财年的销售额为69亿美元，其中31%的销售额来自人类葡萄糖传感器。顶峰公司是一家成熟的生物传感器制造商，能够很好地将这一新型生物传感器推向广阔的市场。

DESCRIPTION (provided by applicant): Abstract In this Phase II SBIR, we will commercialize tissue-implantable 30 μm microbiosensors to measure glucose, lactate and oxygen for use in freely moving animals. We will also develop and commercialize a sensor array composed of a glucose biosensor, a lactate biosensor and an oxygen sensor. Biosensors provide high temporal resolution and low analyte consumption when compared to microdialysis. Current, state-of-the-art biosensors (O.D. 100-250 μm), have proven value in the measurement of a range of analytes in the brains of freely moving rodents. Reduction of biosensor diameter will result in considerably less damage to brain tissue and improved anatomical accuracy over current microdialysis and biosensor techniques. Pinnacle will lead this proposal and work in conjunction with an interdisciplinary consortium of three leading scientists at the University of Kansas. Professor Shenqiang Ren possesses extensive experience in materials science and nanofabrication techniques, Professor Mark Richter is skilled in protein engineering, and Professor George Wilson brings over 30 years of experience in biosensor development to the project. The facilities and equipment available at Pinnacle and the various University of Kansas laboratories will provide the resources required to successfully complete this project. Innovative aspects of this proposal include: new technologies in biosensor manufacturing such as nanoetching, and electrophoretically manipulated enzyme-immobilized nanoparticles and the ability to routinely and precisely deposit picoliters of substrate into a defined well. In Phase I,our team made several significant advancements in the development of a prototype 30 μm glucose microbiosensor. We produced functional prototypes that measured glucose in a linear fashion to at least 20 mM, rejected ascorbate and urate, and efficiently recycled O2 at the electrode surface. These preliminary results form the foundation for the Phase II proposal. These implantable 30 μm microbiosensors have the potential to significantly increase the understanding of the mechanisms behind drug-neuron interactions. This will profoundly change the drug discovery landscape and improve drug development efficiencies for pharmaceutical and biotech companies. In addition, increased spatial resolution and decreased inflammation responses will allow researchers to identify new neural processes, leading to new understandings, approaches and solutions for common maladies. Biosensor sales in FY2009 were $6.9 billion with 31% of the sales due to human glucose sensors. Pinnacle is an established manufacturer of biosensors and is well positioned to introduce this new class of biosensors to a broad market.